Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

A 56-year-old woman, previously treated for breast cancer, presented to gynecologists with a lump of the left labium major of the vulva. The FDG pattern resembled as a cIV stage vulvar cancer, whereas biopsy indicated metastases from breast cancer. Metastatic disease to the vulva is particularly uncommon, representing 5% to 8% of all vulvar cancer lesions. However, gynecological uptakes, including vulvar site, have to be kept in mind as a possible site of metastatic lesions from breast cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002583DOI Listing

Publication Analysis

Top Keywords

breast cancer
16
vulvar cancer
8
cancer
6
18f-fdg pet/ct
4
pet/ct case
4
case metastatic
4
breast
4
metastatic breast
4
cancer vulva
4
vulva 56-year-old
4

Similar Publications

Background: Breast cancer treatment, particularly during the perioperative period, is often accompanied by significant psychological distress, including anxiety and uncertainty. Mobile health (mHealth) interventions have emerged as promising tools to provide timely psychosocial support through convenient, flexible, and personalized platforms. While research has explored the use of mHealth in breast cancer prevention, care management, and survivorship, few studies have examined patients' experiences with mobile interventions during the perioperative phase of breast cancer treatment.

View Article and Find Full Text PDF

Oligomeric proanthocyanidins (OPCs), condensed tannins found plentiful in grape seeds and berries, have higher bioavailability and therapeutic benefits due to their low degree of polymerization. Recent evidence places OPCs as effective modulators of cancer stem cell (CSC) plasticity and tumor growth. Mechanistically, OPCs orchestrate multi-pathway inhibition by destabilizing Wnt/β-catenin, Notch, PI3K/Akt/mTOR, JAK/STAT3, and Hedgehog pathways, triggering β-catenin degradation, silencing stemness regulators (OCT4, NANOG, SOX2), and stimulating tumor-suppressive microRNAs (miR-200, miR-34a).

View Article and Find Full Text PDF